CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Novartis quietly returns a key antibiotic to US market

RegulatoryapprovedLamprenePositive
AI Analysis

Summary

Novartis obtained supplemental FDA approval for Lamprene, a decades-old leprosy drug, enabling its return to the commercial US market.

Outcome Details

supplemental FDA approval

Importance:5/10
Sentiment:
0.60
FDA approvalantibioticleprosysupplemental approvalmarket return
Related Companies

Read the original article

Published by Endpoints News on October 13, 2026 6:51 PM

Read Original